Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

Authors
Francisco Ugarte-Gil, ManuelHanly, JohnUrowitz, MurrayGordon, CarolineBae, Sang-CheolRomero-Diaz, JuanitaSanchez-Guerrero, JorgeBernatsky, SashaClarke, Ann ElaineWallace, Daniel J.Isenberg, David AlanRahman, AnisurMerrill, Joan T.Fortin, Paul R.Gladman, Dafna D.Bruce, Ian N.Petri, MichelleGinzler, Ellen M.Dooley, Mary AnneRamsey-Goldman, RosalindManzi, SusanJonsen, Andreasvan Vollenhoven, Ronald F.Aranow, CynthiaMackay, MegganRuiz-Irastorza, GuillermoLim, SamInanc, MuratKalunian, KenJacobsen, SorenPeschken, ChristineKamen, Diane L.Askanase, AncaPons-Estel, Bernardo A.Alarcon, Graciela S.
Issue Date
Nov-2022
Publisher
BMJ Publishing Group
Keywords
systemic lupus erythematosus; outcome assessment; health care; epidemiology
Citation
Annals of the Rheumatic Diseases, v.81, no.11, pp 1541 - 1548
Pages
8
Indexed
SCIE
SCOPUS
Journal Title
Annals of the Rheumatic Diseases
Volume
81
Number
11
Start Page
1541
End Page
1548
URI
https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/186176
DOI
10.1136/ard-2022-222487
ISSN
0003-4967
1468-2060
Abstract
Objective To determine the independent impact of different definitions of remission and low disease activity (LDA) on damage accrual. Methods Patients with >= 2 annual assessments from a longitudinal multinational inception lupus cohort were studied. Five mutually exclusive disease activity states were defined: remission off-treatment: clinical Systemic Lupus Erythematosus Disease Activity Index (cSLEDAI)-2K=0, without prednisone or immunosuppressants; remission on-treatment: cSLEDAI-2K score=0, prednisone <= 5 mg/day and/or maintenance immunosuppressants; low disease activity Toronto cohort (LDA-TC): cSLEDAI-2K score of <= 2, without prednisone or immunosuppressants; modified lupus low disease activity (mLLDAS): Systemic Lupus Erythematosus Disease Activity Index-2K score of 4 with no activity in major organ/systems, no new disease activity, prednisone <= 7.5 mg/day and/or maintenance immunosuppressants; active: all remaining visits. Only the most stringent definition was used per visit. Antimalarials were allowed in all. The proportion of time that patients were in a specific state at each visit since cohort entry was determined. Damage accrual was ascertained with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Univariable and multivariable generalised estimated equation negative binomial regression models were used. Time-dependent covariates were determined at the same annual visit as the disease activity state but the SDI at the subsequent visit. Results There were 1652 patients, 1464 (88.6%) female, mean age at diagnosis 34.2 (SD 13.4) years and mean follow-up time of 7.7 (SD 4.8) years. Being in remission off-treatment, remission on-treatment, LDA-TC and mLLDAS (per 25% increase) were each associated with a lower probability of damage accrual (remission off-treatment: incidence rate ratio (IRR)=0.75, 95% CI 0.70 to 0.81; remission on-treatment: IRR=0.68, 95% CI 0.62 to 0.75; LDA: IRR=0.79, 95% CI 0.68 to 0.92; and mLLDAS: IRR=0.76, 95% CI 0.65 to 0.89)). Conclusions Remission on-treatment and off-treatment, LDA-TC and mLLDAS were associated with less damage accrual, even adjusting for possible confounders and effect modifiers.
Files in This Item
Go to Link
Appears in
Collections
서울 의과대학 > 서울 내과학교실 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE